Sarah Sammons

16PUBLICATIONS
106CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersHealth and ecological risk assessmentClinical midwifery
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|May 13, 2026
Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor-Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy.

|Nov 14, 2025
Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer.

Sarah Sammons, Denise A Yardley, Priyanka Sharma

|Mar 31, 2025
Prevalence by therapy line and incidence of breast cancer brain metastases in 18 075 patients.

Sarah L Sammons, Thibaut Sanglier, Jose Pablo Leone

|Dec 18, 2024
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.

Kevin Kalinsky, Giampaolo Bianchini, Erika Hamilton

|Dec 05, 2024
Genomic Landscape of Malignant Phyllodes Tumors Identifies Subsets for Targeted Therapy.

Rani Bansal, Tolulope Adeyelu, Andrew Elliott

|Sep 06, 2024
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.

Komal L Jhaveri, Elgene Lim, Rinath Jeselsohn

Pageof 3

Frequent Collaborators

4 joint publications

Carey K Anders

3 joint publications

Amanda E D Van Swearingen

2 joint publications

Lillian Smyth

2 joint publications

Stephanie L Graff